Medical Costs of Adults With COVID-19 in Costa Rica During the Endemic Phase: A Micro-Costing Study

Speaker(s)

Lasalvia P1, Vásquez E1, Baldi-Castro JJ2, Barrantes-Aragon LA2, Villafranca A3, Marcano-Lozada M3, Mendoza CF4, Ochapa M5, Chaverri-Murillo J6, Ramírez-Cardoce M7
1NeuroEconomix, Bogotá, CUN, Colombia, 2Pfizer Central America and The Caribbean, Escazú, SJ, Costa Rica, 3Pfizer Central America and the Caribbean, Escazú, SJ, Costa Rica, 4Pfizer Inc, CDMX, EM, Mexico, 5Morgan State University School of Community Health and Policy, Pfizer Inc, Westerville, OH, USA, 6Hospital Dr. Rafael Ángel Calderón Guardia, Caja Costarricense de Seguro Social, SJ, San José, Costa Rica, 7Hospital San Juan de Dios, Caja Costarricense de Seguro Social, SJ, San José, Costa Rica

OBJECTIVES: Estimate the direct medical costs (per patient) related to the acute management of adult patients with COVID-19, from the national public healthcare system (NPHS) perspective of Costa Rica (Caja Costarricense de Seguro Social [CCSS]).

METHODS: A standardized questionnaire was administered to Costa Rican clinical experts to estimate the Healthcare Resource Utilization (HCRU) for adult patients with COVID-19. The questionnaire considered factors like age group, vaccination status, and risk of severe outcomes. A base case approach identified resource needs for outpatient, general ward, and ICU settings. Unit costs were assigned to these resources based on the latest CCSS´s Model Tariff and other public official records. Costs in local currency were converted to 2023 USD.

RESULTS: Across all age groups, the average cost of outpatient care in high-risk patients was USD$2,811.7 and USD$2,752.0 (unvaccinated and vaccinated, respectively); for low–risk patients the average cost was USD$2,716.3 (unvaccinated) and USD$2,707.3 (vaccinated). In the general ward, the average cost (all age groups) in the high-risk patients was USD$9,051.3 for the unvaccinated and USD$8,409.8 for vaccinated patients, in contrast with USD$8,051.7 (unvaccinated) and USD$7,523.6 (vaccinated) in the low-risk group. In the ICU, the costs increased drastically, being on average USD$40,906.5 and USD$32,709.7 for high-and low-risk patients, respectively, regardless of the vaccination status. The main cost driver in both the ICU and general ward setting was the hospitalization cost (inpatient-stay). Use of mechanical ventilation in the ICU increases costs by USD$15,430.3 more for any age group.

CONCLUSIONS: COVID-19 still causes significant economic costs to CR´s NPHS, even as it becomes endemic. Overall, patients ≥30 years old had higher HCRU/healthcare costs in all cases (ICU and general ward), nonetheless, compared to vaccinated patients, unvaccinated high-and low-risk patients in the general ward had greater consumption of health resources, therefore, they incur higher direct care costs.

Code

EPH89

Topic

Economic Evaluation, Epidemiology & Public Health

Topic Subcategory

Public Health

Disease

Infectious Disease (non-vaccine), Vaccines